Since the publication of our RAPS due diligence book last year, we've been asked if one could apply the lessons we learned from making risk-based analysis of product-based investments to other areas of the pharmaceutical industry. Does anyone have any ideas on these principles might apply to other areas of the industry (e.g., M&A)?
-------------------------------------------
Raymond Huml
Executive Director, Global Due Diligence
Durham NC
United States
-------------------------------------------